The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Los Angeles lawyer gets 87 months in prison for role in money laundering and bribery scheme
February 25, 2026
News Alert
New Post
Jury finds former Corsa Coal VP guilty of money laundering and FCPA violations
February 24, 2026
News Alert